Patients with schizophrenia tend to have deficits in emotion recognition (ER) that affect their social function. However, the commonly-used ER measures appear incomprehensive, unreliable and invalid, making it difficult to comprehensively evaluate ER. The purposes of this study were to develop the Computerized Emotion Recognition Video Test (CERVT) evaluating ER ability in patients with schizophrenia. This study was divided into two phases. First, we selected candidate CERVT items/videos of 8 basic emotion domains from a published database. Second, we validated the selected CERVT items using Rasch analysis. Finally, the 269 patients and 177 healthy adults were recruited to ensure the participants had diverse abilities. After the removal of 21 misfit (infit or outfit mean square > 1.4) items and adjustment of the item difficulties of the 26 items with severe differential item functioning, the remaining 217 items were finalized as the CERVT items. All the CERVT items showed good model fits with small eigenvalues (≤ 2) based on the residual-based principal components analysis for each domain, supporting the unidimensionality of these items. The 8 domains of the CERVT had good to excellent reliabilities (average Rasch reliabilities = 0.84-0.93). The CERVT contains items of the 8 basic emotions with individualized scores. Moreover, the CERVT showed acceptable reliability and validity, and the scores were not affected by examinees' gender. Thus, the CERVT has the potential to provide a comprehensive, reliable, valid, and gender-unbiased assessment of ER for patients with schizophrenia.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1093/arclin/acad098 | DOI Listing |
Psychopharmacology (Berl)
December 2024
Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, Kings College London, De Crespigny Park, London, SE5 8AF, UK.
Rationale: Working memory impairment is a prominent feature of schizophrenia which predicts clinical and functional outcomes. Preclinical data suggest histamine-3 receptor (H3R) expression in cortical pyramidal neurons may have a role in working memory, and post-mortem data has found disruptions of H3R expression in schizophrenia.
Objectives: We examined the role of H3R in vivo to elucidate its role on working memory impairment in schizophrenia.
Objective In 2020, > 6 million individuals with mental disorders received psychiatric care. Advocacy is important to ensure that the rights of psychiatric patients, for whom involuntary hospitalization sometimes occurs, are maintained. This study aimed to develop a Japanese version of the Patient Self-Advocacy Scale (PSAS) by Brashers et al.
View Article and Find Full Text PDFBiol Psychiatry Cogn Neurosci Neuroimaging
December 2024
Background: Phenomenological psychopathologists have recently highlighted how people with delusions experience multiple realities (delusional and non-delusional) and have suggested this double bookkeeping cannot be explained via predictive processing. Here, we present data from Kamin blocking and extinction learning that show how predictive processing might, in principle, explain a pervasive sense of dual reality.
Methods: This cross-sectional study involved three participant groups: patients with schizophrenia (SZ; n=42), healthy participants with elevated esoteric beliefs (EEB; clairaudient psychics; n=31), and heathy controls (with neither illness nor significant delusional ideation, n=62).
Salud Colect
December 2024
Doctor en Sociología. Académico, Departamento de Trabajo Social, Facultad de Ciencias Sociales, Universidad Alberto Hurtado, Santiago, Chile.
This article analyzes the impact of psychotropic drug use on individuals diagnosed with schizophrenia, bipolar affective disorder, and severe depression in Chile. Using a qualitative narrative approach, the experiences of 25 patients from 2018 to 2021 are examined. Participants describe how these medications, while effective in symptom control, generate psychological suffering and a sense of coercion in daily life.
View Article and Find Full Text PDFNeuropharmacology
December 2024
NeurWrite LLC, Morristown, NJ, USA.
Background: Evenamide, a glutamate modulator, is currently in phase 3 of development as add-on treatment to antipsychotics in patients with inadequate response or treatment-resistant schizophrenia. This study was designed to determine if patients with chronic schizophrenia inadequately responding to a second-generation antipsychotic would benefit from add-on treatment with evenamide at a dose of 30 mg bid.
Methods: Study 008A was a prospective, 4-week, randomized, double-blind, placebo-controlled study evaluating the safety, tolerability, and efficacy of oral doses of evenamide of 30 mg bid in patients with chronic schizophrenia treated at stable therapeutic doses of a second-generation antipsychotic.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!